Product Description
Oxycodone has been in clinical use since 1917. Parenteral oxycodone was used mainly for the treatment of acute postoperative pain whereas combinations, for example, oxycodone and acetaminophen, were used for moderate pain. Since the introduction of controlled-release oxycodone, it has been used to manage cancer-related pain and chronic non-cancer-related pain problems. Oxycodone closely resembles morphine but it has some distinct differences, particularly in its pharmacokinetic profile. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/15907646/)
Mechanisms of Action: OPR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Pain Unspecified | Pain Unspecified | Pain Unspecified | Substance Abuse Unspecified | Acute Pain | Chronic Pain | Pain Unspecified | Substance Abuse Unspecified
Known Adverse Events: Dizziness | Headache | Pruritus | Asthenia | Constipation | Insomnia
Company: Mundipharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Brazil, China, United States
Active Clinical Trial Count: 9
Highest Development Phases
Phase 3: Labor Pain|Pain, Postoperative
Phase 2: Cancer Pain
Phase 1: Acute Pain|Chronic Pain|Drug Overdose|Healthy Volunteers|Pain Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 3D1002-CN-001 | P2 |
Not yet recruiting |
Cancer Pain |
2025-12-01 |
|
| PF614-MPAR-102 | P1 |
Recruiting |
Drug Overdose |
2025-09-01 |
|
| OXIFEN | P3 |
Recruiting |
Pain, Postoperative|Labor Pain |
2025-05-28 |
95% |
| OXIFEN | P3 |
Recruiting |
Pain, Postoperative|Labor Pain |
2025-05-28 |
95% |
| MPAR-101 | P1 |
Completed |
Healthy Volunteers |
2023-04-26 |